European Journal of Neurology· 2019Q1· Review
Parkinson disease
- 1,462citations
- Q1SCImago
- 2019year
Short summary
Parkinson disease (PD) is a common neurodegenerative movement disorder characterized by dopaminergic neuron loss and alpha-synuclein accumulation, with current treatments managing motor symptoms but not disease progression.
AI-generated from the title and abstract; the full text is not read.
Key points
- Parkinson disease (PD) is the most common neurodegenerative movement disorder.
- Prevalence in Europe is estimated at 108-257/100,000, with incidence at 11-19/100,000 annually.
- Pathology includes dopaminergic neuron loss in the substantia nigra and alpha-synuclein accumulation in Lewy bodies.
- Diagnosis is primarily clinical, supported by investigations for differential diagnosis.
- Current treatments manage motor symptoms but do not modify disease progression.
AI-generated from the title and abstract; the full text is not read.
Abstract
Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108-257/100 000 and 11-19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors. The aetiology of the disease in most patients is unknown, but different genetic causes have been identified. Although familial forms of PD account for only 5%-15% of cases, studies on these families provided interesting insight on the genetics and the pathogenesis of the disease allowing the identification of genes implicated in its pathogenesis and offering critical insights into the mechanisms of disease. The cardinal motor symptoms of PD are tremor, rigidity, bradykinesia/akinesia and postural instability, but the clinical picture includes other motor and non-motor symptoms. Its diagnosis is principally clinical, although specific investigations can help the differential diagnosis from other forms of parkinsonism. Pathologically, PD is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by accumulation of misfolded α-synuclein, which is found in intra-cytoplasmic inclusions called Lewy bodies. Currently available treatments offer good control of motor symptoms but do not modify the evolution of the disease. This article is intended to provide a comprehensive, general and practical review of PD for the general neurologist.
The authors' abstract, as published at the source. European Journal of Neurology, 2019 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Neurology (Medicine)
NeurologyMedicine